Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dual targeting of tafi and pai-1

a technology of tafi and pai, which is applied in the field of treatment and prevention of thrombotic disorders, can solve the problems of reducing the activity of tafi, affecting the thrombolytic function of patients, and reducing so as to reduce the risk of intracranial haemorrhage and short activity, the effect of reducing the size of the lesion

Active Publication Date: 2017-09-07
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0027]The methods of the present invention wherein a diabody against TAFI and PAI-1 is used have, compared to tPA, less risks of causing intracranial haemorrhage and neurotoxicity. The diabodies of the present invention are of use in reducing lesion size in patients suffering from a brain lesion. Brain lesions may be caused by thrombotic disorders, such as stroke, acute ischemic stroke (AIS), and / or middle cerebral artery occlusion (MCAo).
[0028]Compared to tPA which has short activity upon administration (about 15 minutes), diabodies can bind to their targets for a much longer time period.
[0029]High doses of tPA can result in unwanted enzymatic activity of plasmin. The use of a high dose of diabody is less critical. Antibody which does not bind PAI-1 or TAFI has no side effects.
[0030]Compared to tPA, the diabodies show a reduction in bleeding time. Accordingly the diabodies of the present invention have the advantageous property of reducing the risk of unwanted bleeding, such as intracranial haemorrhage.

Problems solved by technology

While effective when administered soon after the event, plasminogen activators also cause debilitating side effects such as intracranial haemorrhage and neurotoxicity.
In addition, successful restoration of blood flow is not guaranteed because of low recanalization and high reocclusion rates, even when high doses of plasminogen activators are administered [Saver J L. et al.
However, the results did not consistently indicate that dual inhibition of TAFI and PAI-1 improved thrombolysis as compared to single inhibition.
However, no dual targeting studies to date have conclusively demonstrated a role for inhibitors or diabodies in treating specific thrombotic disorders in vivo.
In addition, no studies have provided evidence for viable treatments for thrombotic disorders based on inhibitors of fibrinolysis or thrombolysis as alternatives to plasminogen activators.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dual targeting of tafi and pai-1
  • Dual targeting of tafi and pai-1
  • Dual targeting of tafi and pai-1

Examples

Experimental program
Comparison scheme
Effect test

example 1

Improving Expression and Efficacy of an Unstable Bispecific Inhibitor (Db-RT36A3F5×33H1F7) Against TAFI and PAI-1 Through Antibody Engineering

A. CDR-Grafting to Engineer Stable Variable Domains

[0095]In a previous study, scFv-RT36A3F5 was generated, but could not be produced by bacteria and corresponding Db-RT36A3F5×33H1F7 was found to be unstable resulting in a diminished effect on clot lysis. Thus, the variable domains of MA-RT36A3F5 were optimized by complementarity determining region (CDR)-grafting onto the stable scaffolds of scFv-4D5 (FIG. 1A) [Jung S. & Plückthun A. (1997) Protein Eng. 10, 959-966. This article discloses the 4D5 humanised antibody used in the CDR grafting]. Two approaches were performed: (i) structure alignment-based strategy of scFv-RT36A3F5 and of scFv-4D5, generating scFv-RT36A3F5-4D5DM (in collaboration with prof Marc Demaeyer) and (ii) evidence-based strategy, generating scFv-RT36A3F5-4D5 [Ewert S. et al. (2004) Methods. 34, 184-199]. The latter approach ...

example 2

In Vitro Evaluation of the Profibrinolytic Properties of a Novel Bispecific Inhibitor Against TAFI and PAI-1

A. Generation of Db-TCK26D6×33H1F7

[0100]Based on the successful generation of stable scFvs with preserved inhibitory capacity of the respective parental antibodies (MA-TCK26D6 and MA-33H1F7), Db-TCK26D6×33H1F7 was generated. This diabody contains two polypeptide chains as depicted in FIG. 2 left bottom. The first one is a fusion protein of the VH chain of the anti TAFI antibody and the VL chain of the anti PAI-1 antibody. The second one is a fusion protein of the VL chain of the anti TAFI antibody and the VH chain of the anti PAI-1 antibody.

[0101]The production level of Db-TCK26D6×33H1F7 was approximately 2 mg / L culture.

B. Characterization of the Inhibitory Effect Towards TAFI and PAI-1

[0102]Inhibitory properties of the parental antibodies against human and mouse TAFI and PAI-1 were preserved in Db-TCK26D6×33H1F7 as confirmed by functional assays. Moreover, Db-TCK26D6×33H1F7 r...

example 3

In Vivo Evaluation of the Profibrinolytic Properties of a Bispecific Inhibitor Against TAFI and PAI-1

1. Complementary Effect of Dual TAFI / PAI-1 Inhibition After Systemic Thrombotic Challenge

[0106]Mice, pre-treated with a dose of MA-TCK26D6 or MA-33H1F7 targeting all circulating antigen, were subjected to thromboembolism by systemic administration of thromboplastin. Fibrin deposition in lungs was only decreased to baseline levels upon administration of a TAFI inhibitor (FIG. 5). Since PAI-1 levels are extremely low in mice, no effect of PAI-1 inhibition was detected.

[0107]To evaluate simultaneous inhibition of TAFI and PAI-1 in this model, endotoxemia was induced to upregulate PAI-1 levels in plasma. Fibrin deposition in the lungs was reduced through TAFI inhibition with MA-TCK26D6 (5 mg / kg) or through PAI-1 inhibition with MA-33H1F7 (10 mg / kg). However, this reduction did not reach a maximal degree. After administering a mixture of MA-TCK26D6 (5 mg / kg) and MA-33H1F7 (10 mg / kg), fibr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
body weightaaaaaaaaaa
Login to View More

Abstract

Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

Description

FIELD OF INVENTION[0001]The present invention relates generally to treatment and prevention of thrombotic disorders such as stroke and thromboembolism by dual inhibition of plasminogen activator inhibitor 1 (PAI-1) and Thrombin-Activatable Fibrinolysis Inhibitor (TAFI). The dual inhibition may be mediated by a bispecific antibody derivative that binds to both targets.REFERENCE TO SEQUENCE LISTING SUBMITTED VIA EFS-WEB[0002]This application includes an electronically submitted sequence listing in .pdf format. The .pdf file contains a sequence listing entitled “19893-18-Sequence_Listing.pdf” created on Aug. 5, 2016 and is 43 bytes in size. The sequence listing contained in this .pdf file is part of the specification and is hereby incorporated by reference herein in its entirety.BACKGROUND[0003]Following an acute cardiovascular accident, the only treatment currently available to recanalize an occluded blood vessel is systemic delivery of a high dose of plasminogen activators. While eff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/38
CPCC07K16/38C07K2317/31A61K2039/505C07K2317/24C07K2317/76C07K2317/565C07K2317/622C07K2317/626C07K16/468G01N2800/22A61P7/02A61P9/10C07K2317/56
Inventor DECLERCK, PAULDE MEYER, SIMONGEUKENS, NICKGILS, ANNRUBIO, MARINAVIVIEN, DENISWYSEURE, TINE
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com